CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-16 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −400 | $42.52 | $17K | 507,630 |
| 2021-02-16 | Hagen Brett R Chief Accounting Officer | Sale | −2,750 | $41.82 | $115K | 68,926 |
| 2021-02-16 | Hagen Brett R Chief Accounting Officer | Sale | −300 | $42.67 | $13K | 68,626 |
| 2021-02-02 | Melian Agustin Chief Medical Officer | Sale | −54,849 | $41.19 | $2.3M | 520,266 |
| 2021-02-02 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −48,910 | $41.19 | $2.0M | 510,730 |
| 2021-01-21 | Hallal David Chief Executive Officer | Grant or award | +147,000 | 2,230,666 | ||
| 2021-01-21 | Hallal David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +273,000 | 273,000 | ||
| 2021-01-19 | Atillasoy Ercem | Grant or award | +28,000 | 106,500 | ||
| 2021-01-19 | Atillasoy Ercem | Grant or award · Stock Option (Right to Buy) | +52,000 | 52,000 | ||
| 2021-01-19 | Melian Agustin Chief Medical Officer | Grant or award | +43,750 | 575,115 | ||
| 2021-01-19 | Melian Agustin Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +81,250 | 81,250 | ||
| 2021-01-19 | Sinha Vikas Director | Grant or award | +58,800 | 865,407 | ||
| 2021-01-19 | Sinha Vikas Director | Grant or award · Stock Option (Right to Buy) | +109,200 | 109,200 | ||
| 2021-01-19 | Hagen Brett R Chief Accounting Officer | Grant or award | +17,500 | 71,676 | ||
| 2021-01-19 | Hagen Brett R Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +32,500 | 32,500 | ||
| 2021-01-19 | Leen Ann M. Chief Scientific Officer | Grant or award | +28,000 | 28,000 | ||
| 2021-01-19 | Leen Ann M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +52,000 | 52,000 | ||
| 2021-01-19 | Miller Edward General Counsel | Grant or award | +28,000 | 194,051 | ||
| 2021-01-19 | Miller Edward General Counsel | Grant or award · Stock Option (Right to Buy) | +52,000 | 52,000 | ||
| 2021-01-19 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award | +35,000 | 559,640 |
Page 25 of 27 · 527 trades